Sowers J R, Pekary A E, Hershman J M, Kanter M, DiStefano J J
J Endocrinol. 1979 Jan;80(1):83-9. doi: 10.1677/joe.0.0800083.
The immunoreactivity of a commercial preparation of human chorionic gonadotrophin (HCG) was determined in a homologous double antibody radioimmunoassay for HCG using antisera to the beta-subunit of the hormone. The immunoreactivity of the commercial HCG was found to be 2.2 +/- 0.3 (mean +/- 2 S.D.) times the biological potency. Exclusion chromatography of the commercial HCG and then curve resolution of the elution profile derived from the radioimmunoassay revealed that on a molar basis, 21% of the immunoreactivity was attributable to beta-HCG. The rate of clearance of this preparation of HCG from the plasma after intravenous administration was determined as a function of the dose administered to ten normal men (age 36--64 years). The doses ranged from 10,000 to 300,000 i.u. immunological potency. The rate of clearance decreased significantly (r = 0.574, P less than 0.05) with increasing doses of HCG from a mean of 786 ml/h at the lowest dose to a mean of 298 ml/h at the highest dose. The renal clearance of administered HCG also decreased with increasing doses; the mean renal clearance of the 10,000 i.u. dose was 3.6 times the mean renal clearance after administration of 200,000 i.u. When the accumulated urinary HCG was expressed as a percentage of the dose administered, 14.1% of the 10,000 i.u. dose and 9.8% of the higher doses accumulated in the urine, suggesting that non-renal clearance increased with increasing dose.
在使用针对人绒毛膜促性腺激素(HCG)β亚基的抗血清进行的HCG同源双抗体放射免疫分析中,测定了一种市售人绒毛膜促性腺激素制剂的免疫反应性。发现该市售HCG的免疫反应性是生物活性的2.2±0.3(平均值±2标准差)倍。对市售HCG进行排阻色谱分析,然后对放射免疫分析得到的洗脱图谱进行曲线解析,结果显示,以摩尔计,21%的免疫反应性归因于β-HCG。将该HCG制剂静脉注射给10名正常男性(年龄36 - 64岁),并根据给药剂量测定其从血浆中的清除率。剂量范围为10,000至300,000国际单位免疫活性。随着HCG剂量的增加,清除率显著降低(r = 0.574,P < 0.05),从最低剂量时的平均786毫升/小时降至最高剂量时的平均298毫升/小时。给药的HCG的肾清除率也随剂量增加而降低;10,000国际单位剂量的平均肾清除率是200,000国际单位给药后平均肾清除率的3.6倍。当累积尿HCG以给药剂量的百分比表示时,10,000国际单位剂量的14.1%和较高剂量的9.8%累积在尿液中,这表明非肾清除率随剂量增加而增加。